Biomarkers

Share:
ResearchersAgainstAlzheimer's would like to thank Roche Diagnostics for their support of this project.
Return to the full list of Biomarkers

Synaptic Injury and Functional Connectivity

Method of Measurement (Pre-analytical Tools)
Imaging
CSF
Biomarker Measured
Neuronal damage
Use
Diagnostic
Stage of Development
Clinical trials
Active vs Completed Trials
Active
Aim/Results

Aim 1: Investigate correlations between CSF biomarkers of synaptic injury (Ng and SNAP-25) and functional connectivity (FC) within the default mode network (DMN) using resting-state fMRI (adjusting for age, gender, apolipoprotein-E4 [APOE4] genotype, task performance, and regional brain atrophy) in MCI/AD and controls. Aim 2: Examine correlations between CSF biomarkers of synaptic injury and functional connectivity (FC) within the semantic memory network on task-activated fMRI using the Famous Name Discrimination Task (FNDT) (adjusting for age, gender, APOE4 genotype, task performance, and regional brain atrophy) in MCI/AD and controls.

Target Population/ Population Being Studied

MCI due to AD or mild AD dementia

Length of Current Trial
4 months
Number of Trial Participants

30

Estimated Trial Completion
December 2019
What is Required from Patients

Invasive lumbar puncture, discomfort, recovery time in clinic to decrease risk of spinal fluid leakage , entering an fMRI machine (can induce claustrophobia)

What is Required from the Health System

physican who can preform a lumbar puncture as well as a clinic designed for this testing, equipped lab (e.g., centrifuge), a way to measure the peptide (e.g.,mass spectrometer, protein assay kit, ELISA, or western blot), fMRI machine, technicine

Sponsor

Ohio State University

“Synaptic Injury and Functional Connectivity in Alzheimer's Disease.” ClinicalTrials.gov. Accessed October 11, 2019. https://clinicaltrials.gov/ct2/show/NCT03300726?term=biomarker&recrs=abdf&cond=Alzheimer+Disease&rank=5